Hemophilia - Pipeline Assessment and Market Forecasts to 2017

Introduction

GlobalData, the industry analysis specialist, has released its new report, “Hemophilia - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData’s analysis suggests that the global hemophilia therapeutics market was valued at $6.5 billion in 2009. It is expected to increase at a Compound Annual Growth Rate (CAGR) of 5.8% from $6.5 billion in 2009 to $10.4 billion by 2017. This slow growth of 5.8% is primarily attributed to a low diagnosis rate and the high cost of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX, a clotting factor from Pfizer Inc.

Scope

The report provides information on the key drivers and challenges of the hemophilia market. Its scope includes:
- Annualized global hemophilia market revenues data from 2001 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include Recombinant coagulation factors (VIIa, VIII,IX), plasma derived coagulation factors, thrombin generation, gene therapy, stem cell therapy, fast acting recombinant Factor VIIa, long acting Factor VIIa and monoclonal antibodies.
- Analysis of the current and future competition in the global hemophilia market. Key market players covered are Baxter Healtcare Corporation, Novo Nordisk, Bayer Healtcare Pharmaceuticals, Pfizer Inc, PTC Therapeutics Inc., Recloy N.V., Ipsen S.A and Biogen Idec Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the hemophilia therapeutics market.

Highlights

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global hemophilia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global hemophilia market landscape? – Identify, understand and capitalize.

Companies Mentioned

Bayer Healthcare (Bayer Schering Pharma AG)
PTC Therapeutics
Hemophilia Pipeline Portfolio
Novo Nordisk
Baxter International
Recoly N.V.
Hemophilia Pipeline Portfolio
[Cerrar las informaciones del articulo de mercado]

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Hemophilia Therapeutics: Introduction 5
2.1 Disease Overview 5
2.2 Diagnosis 6
2.3 Treatment and Management of Hemophilia 6
2.3.1 Factor Concentrates 6
2.3.2 Recombinant Coagulation Factors 6
2.3.3 Cryoprecipitate 6
2.3.4 Fresh Plasma 6
2.3.5 Whole Blood 7
2.4 Inhibitors 8
2.5 Acquired Hemophilia 8
2.5.1 Treatment of Acquired Hemophilia 8
2.6 Epidemiology 8
2.7 GlobalData Pipeline Report Guidance 9
3 Hemophilia Therapeutics: Market Characterization 10
3.1 Hemophilia Therapeutics Market Size 10
3.2 Hemophilia Therapeutics Market Forecast and CAGR 11
3.3 Drivers and Barriers for the Hemophilia Therapeutics Market 12
3.3.1 Drivers for the Hemophilia Therapeutics Market 12
3.3.2 Barriers for the Hemophilia Therapeutics Market 12
3.4 Opportunity and Unmet Need 13
3.5 Key Takeaway 13
4 Hemophilia Therapeutics Market: Competitive Assessment 14
4.1 Overview 14
4.2 Strategic Competitor Assessment 14
4.3 Product Profile for the Major Marketed Products in the Hemophilia Therapeutics Market 15
4.3.1 NovoSeven (Novo Nordisk) 15
4.3.2 Advate (Baxter International) 16
4.3.3 Kogenate FS (Bayer Healthcare) 16
4.3.4 XYNTHA (Pfizer) 17
4.3.5 BeneFIX (Pfizer) 18
4.3.6 FEIBA-VH (Baxter International) 18
4.3.7 Octaplex (Octapharma) 19
4.4 Key Takeaway 19
5 Hemophilia Therapeutics Market: Pipeline Assessment 20
5.1 Overview 20
5.2 Strategic Pipeline Assessment 20
5.2.1 Technology Trends Analytic Framework 20
5.3 Molecule Profile for Promising Drugs under Clinical Development 22
5.3.1 Ataluren (PTC124) 22
5.3.2 NecLip-rFVIIa (LongSeven) 23
5.3.3 NecLip-pdFVIII (LongAte) 23
5.4 Hemophilia Therapeutics Market – Clinical Pipeline by Mechanism of Action 24
5.4.1 Hemophilia Therapeutics Pipeline – Pipeline by Clinical Phase of Development 25
5.4.2 Hemophilia Therapeutics, Phase III Clinical Pipeline 25
5.4.3 Hemophilia Therapeutics – Phase II Clinical Pipeline 26
5.4.4 Hemophilia Therapeutics, Phase I Clinical Pipeline 26
5.4.5 Hemophilia Therapeutics, Discovery and Preclinical Pipeline 27
5.5 Key Takeaway 27
6 Hemophilia Therapeutics Market: Implications for Future Market Competition 28
7 Hemophilia Therapeutics Market: Future Players in the Hemophilia Therapeutics Market 29
7.1 Introduction 29
7.2 Bayer Healthcare (Bayer Schering Pharma AG) 30
7.2.2 Hemophilia Portfolio 30
7.3 PTC Therapeutics 30
7.3.1 Overview 30
7.3.2 Hemophilia Portfolio 30
7.4 Hemophilia Pipeline Portfolio 31
7.4.1 Ataluren (PTC124) 31
7.5 Novo Nordisk 32
7.5.1 Overview 32
7.5.2 Hemophilia Portfolio 32
7.6 Baxter International 33
7.6.1 Overview 33
7.6.2 Financial Performance 33
7.6.3 Hemophilia Portfolio 33
7.7 Recoly N.V. 33
7.7.1 Overview 33
7.7.2 Hemophilia Portfolio 33
7.8 Hemophilia Pipeline Portfolio 34
7.8.1 NecLip-rFVIIa (LongSeven) 34
8 Hemophilia Therapeutics Market: Appendix 35
8.1 Definitions 35
8.2 Acronyms 35
8.3 Research Methodology 36
8.3.1 Coverage 36
8.3.2 Secondary Research 36
8.3.3 Forecasting 36
8.3.4 Primary Research 39
8.3.5 Expert Panel Validation 39
8.4 Contact Us 39
8.5 Disclaimer 39
8.6 Sources 40
[Cerrar la tabla de contenidos]

Table 1: Bleeding Manifestations in Hemophilia 5
Table 2: Hemophilia Bleeding Sites 5
Table 3:Consumption Breakdown of Factor Concentrates 7
Table 4: Patients Diagnosed in 2008 8
Table 5: Hemophilia Therapeutics Market, Global, Revenues ($bn), 2001-2009 10
Table 6: Hemophilia Therapeutics Market, Global, Revenue ($bn), 2009-2017 11
Table 7: Hemophilia Therapeutics, Filed and Phase III Clinical Pipeline, December 15, 2010 25
Table 8: Hemophilia Therapeutics, Phase II Clinical Pipeline, December 15, 2010 26
Table 9: Hemophilia Therapeutics – Phase I Clinical Pipeline, December 15, 2010 26
Table 10: Hemophilia Therapeutics, Discovery and Preclinical Pipeline, December 15, 2010 27
Table 11: Bayer Healthcare, Hemophilia Pipeline Products, 2010 30
Table 12: PTC Therapeutics, Inc., Hemophilia Pipeline Products, 2010 30
Table 13: Novo Nordisk, Hemophilia Pipeline Products, 2010 32
Table 14: Baxter International, Hemophilia Pipeline Products, 2010 33
Table 15: Recoly N.V., Hemophilia Pipeline Products, 2010 33

Figure 1: Key Aspects of the Management of Hemophilia 7
Figure 2: Hemophilia Therapeutics Market, Global, Revenues ($bn), 2001-2009 10
Figure 3: Hemophilia Therapeutics Market, Global, Revenue ($bn), 2009-2017 11
Figure 4: Opportunity and Unmet Need in the Hemophilia Therapeutics Market, 2010 13
Figure 5: Strategic Competitor Assessment of the Major Marketed Products for Hemophilia, 2010 14
Figure 6: Technology Trends Analytic Framework of the Hemophilia Pipeline, December 15, 2010 20
Figure 7: Technology Trends Analytic Framework of the Hemophilia Pipeline, Description, 2010 21
Figure 8: Hemophilia Therapeutics, Global, Clinical Pipeline by Mechanism of Action, 2010 24
Figure 9: Hemophilia Therapeutics Pipeline by Phase of Clinical Development, December 15, 2010 25
Figure 10: Implications for Future Market Competition in the Hemophilia Therapeutics Market, 2010 28
Figure 11: Hemophilia Therapeutics Market, Clinical Pipeline by Company December 15, 2010 29
Figure 12: GlobalData Market Forecasting Model 38
[Ocultar lista de tablas / figuras]